| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.24 | 6e-08 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.8 | 4e-05 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.13 | 6e-05 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.0005 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.002 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.003 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.14 | 0.003 |